Strybrotism
What is Strybrotism?
"Strybrotism is a condition induced through injection of the Nexyra serum. Subjects present one of three primary outcomes: Erosium, in which systemic degradation leads to fatal collapse; Axiom marks minor physiological or cognitive alterations; or Scient, characterized by extraordinary anomalous manifestation. Individual outcomes vary significantly and remain largely unpredictable. Current efforts are focused on improving survival rates, though consistent control over post-exposure has yet to be achieved."
- Dr. Hendrix
Transmission & Vectors
Strybrotism is acquired through direct injection of the Nexyra serum. It is not contagious and does not spread through contact or environmental exposure. Congenital manifestation has been observed in second-generation cases.
Causes
Exposure to the engineered Nexyra serum.
Symptoms
Strybrotism presents across a spectrum. Not all subjects exhibit the same level of manifestation.
Axiom
The subject exhibits minor physiological or cognitive enhancement. Typically stable and does not significantly impact daily function.
Scient
The subject displays high-order anomalous abilities, including psychic or reality-influencing manifestations. Cases are associated with elevated neurological and metabolic strain.
Treatment
There are currently no known treatments. Once administered, Nexyra exposure cannot be reversed.
Prognosis
Outcomes vary depending on the individual and stability.
Erosium
Progressive cellular and neurological degradation marked by loss of physiological coherence. The condition is frequently terminal.
Sequela
Long-term outcomes vary widely. In some cases, residual enhancement or anomalous traits persist without further progression. In others, lasting physiological, neurological, or psychological consequences may develop, even after stabilization. Regardless of severity, individuals with Strybrotism are frequently subject to prolonged monitoring, classification, or restriction, and may face lasting social or institutional consequences.
Affected Groups
A wide range of subjects has been affected during repeated attempts to establish reliable patterns in Nexyra’s effects.
Prevention
No medical prevention exists. Prevention is limited to avoiding exposure to Nexyra and entities capable of administering it.
Epidemiology
Documented cases are extremely rare and primarily associated with controlled experimental exposure. Incidence in the general population is negligible. Congenital manifestation has been observed in limited second-generation cases.
History
The condition now known as Strybrotism was initially observed in isolated experimental subjects exposed to Nexyra. Early records treated these outcomes as anomalous successes rather than a distinct condition. Only after repeated cases, and the emergence of inherited traits, did formal classification occur, though its true origins remain contested.
Cultural Reception
Public awareness of Strybrotism is effectively nonexistent. Within informed circles, surviving individuals are viewed as exceptionally rare and are frequently assessed for their strategic or utilitarian value.
Comments